Your browser doesn't support javascript.
loading
Etiological and prognostic values of procalcitonin in hospital-acquired pneumonia
Egyptian Journal of Chest Diseases and Tuberculosis [The]. 2014; 63 (1): 201-206
em Inglês | IMEMR | ID: emr-154314
ABSTRACT
Biological markers such as procalcitonin, may be helpful for the diagnosis of HAP. Procalcitonin has greater diagnostic accuracy than most commonly used clinical parameters and other biomarkers of infection, such as C-reactive protein and ESR. The aim of the study was to assess the etiological and prognostic values of procalcitonin in adult patients with hospital acquired pneumonia [HAP]. 15 Patients with a strong suspicion of hospital acquired pneumonia. The diagnosis of HAP depends on the clinical criteria of pulmonary infection and presence of radiological findings. Complete blood picture, sputum culture and sensitivity, ESR, CRP and PCT were obtained at admission and repeated after 2 weeks. PCT was determined with Elecsys BRAHMS PCT in serum >f studied patients. Serum PCT above 0.5 microg/L was considered highly positive for diagnosis of HAP. It was significantly higher at admission [2.72 +/- 1.72 microg/L] than after two weeks [1.0 +/- 1.91 microg/L]. There was a statistical significant decrease in serup levels of procalcitonin [P = 0.002] in response to antibiotic therapy. Also the PCX was significantly higher in patients with bad outcome [2.11-6.0 microg/L] than patients with good outcome [1.76 +/- 0.69 microg/L]. Procalcitonin was significantly higher among patients with pseudomonas [5.53 +/- 0.50 microg/L] and acinetobacter [2.67 +/- 0.49 microg/L] and lesser among patients with Escherichia coli [1.38 +/- 0.06 microg/L] and MRSA [1.09 +/- 0.13 microg/L]. Procalcitonin was a good etiological and prognostic marker in hospital acquired pneumonia. PCX is the most specific biomarker and has a number of advantages over previous markers
Assuntos
Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Prognóstico / Biomarcadores / Resultado do Tratamento / Receptores Citoplasmáticos e Nucleares Idioma: Inglês Revista: Egypt. J. Chest Dis. Tuberc. Ano de publicação: 2014

Similares

MEDLINE

...
LILACS

LIS

Buscar no Google
Índice: IMEMR (Mediterrâneo Oriental) Assunto principal: Prognóstico / Biomarcadores / Resultado do Tratamento / Receptores Citoplasmáticos e Nucleares Idioma: Inglês Revista: Egypt. J. Chest Dis. Tuberc. Ano de publicação: 2014